At Caligor Coghlan Pharma Services (CCPS) our Early Access to Medicines (EAM) services are designed with one goal in mind: to expand access to treatment so more people benefit from the impact of innovative medicines.
Our EAM team has a background in the clinical trial world and each of or our team members have been part of global orphan and rare disease drug development and global clinical trials. These skills have been transferred over to the unique world of “Early Access to Treatments”. We have the skills and experience to design, set up and manage these unique programs around the world, providing both the client and physicians with expert support throughout the process. In addition, our Regulatory Affairs and Strategic Services group can assist you with a range of services supporting drug and device development from concept to commercialization.
Clinigen make sure healthcare professionals with a patient in need, anywhere in the world, can always get the right medicine for their individual patient – quickly, easily and safely whether licensed or unlicensed.
Bionical Emas EAP is the only specialist Early Access Program (EAP) partner to harness the full power of an established and successful Clinical Research Organization. Our global EAP experience in Oncology and rare disease areas is perfectly complemented by a range of in-house services.
The Bionical Emas EAP team provides our clients a superior experience for the benefit of healthcare professionals and patients around the world.
Our mission is to positively impact the lives of patients and their families all around the world. Our goal is to help current and future generations providing timely and appropriate treatment access to patients in desperate need.